Showing results (121-130 of 158) with videos related to
Sort By:
Pageof 16
Journal of Hepatology|July 8, 2014
Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver diseasePrue M Pereira-Fantini, Susan Lapthorne, Susan A Joyce, et al.European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trialAxel Le Cesne, Martine Van Glabbeke, Jaap Verweij, et al.Medical Oncology (Northwood, London, England)|August 22, 2018
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcomaAlexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, et al.Cancer Research|October 20, 2004
A gene expression signature associated with metastatic outcome in human leiomyosarcomasYin-Fai Lee, Megan John, Alison Falconer, et al.Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.Acta Oncologica (Stockholm, Sweden)|April 23, 2017
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 studyRobin J Young, Saskia Litière, Michela Lia, et al.Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.Cancer|February 3, 2011
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcomaAntoine Italiano, Armelle Laurand, Audrey Laroche, et al.Pageof 16